NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Tuesday that revenues for its fourth quarter rose 51 percent year over year.

The South San Francisco, Calif.-based firm recorded $6.8 million in revenues for the three months ended Dec. 31, 2013, up from $4.5 million in the year-ago fourth quarter. In a statement, Veracyte President and CEO Bonnie Anderson said, "We saw increases in fine needle aspiration sample volumes and cash collections during the fourth quarter, which is traditionally our strongest quarter."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.